Deals: Page 2

AbbVie keeps up dealmaking pace in neuroscience

On the heels of its Syndesi acquisition, the company has announced an agreement with Gedeon Richter focused on researching and developing new dopamine-regulating drugs for neuropsychiatric diseases.

By Jacob Bell • March 11, 2022

After slower-than-expected review, Pfizer and Arena close buyout deal

Pfizer officially closed its $7 billion acquisition of Arena Pharmaceuticals on Friday without needing to divest any assets.

By Jacob Bell • Updated March 11, 2022

Explore the Trendline➔

The BioPharma Dive Outlook on 2022

After surging into 2021, biotech crashed at the end of last year amid negative clinical trial readouts, ebbing M&A and broader investor pullback. But the year ahead figures to be busy on several fronts and a slate of important studies could deliver good news. 

By BioPharma Dive staff

Novartis turns to Voyager for nervous system gene therapies

The deal, which carries a $54 million upfront payment, could give Novartis access to as many as five of Voyager's capsids, which would be used to develop gene therapies for the central nervous system.

By Jacob Bell • March 8, 2022

Bluebird's CFO resigns as cash woes raise doubts about its future

The gene therapy developer's top financial executive, Gina Consylman, is stepping down amid concerns the company needs to raise additional cash to survive for more than a year.  

By Jonathan Gardner • March 7, 2022

Viatris sells off biosimilars business in $3.3B deal

The sale to Biocon represents the first major step Viatris has taken to reshape itself, following a strategic review that took place throughout 2021.

By Jacob Bell • Feb. 28, 2022

Biohaven stocks up on experimental drugs with new acquisition, licensing deal

Separate agreements with Channel Biosciences and Bristol Myers Squibb give Biohaven access to experimental treatments for spinal muscular atrophy and for epilepsy.

By Jacob Bell • Feb. 25, 2022

Copay accumulators, maximizers and the CMS best price rule: What you need to know now

Copay accumulators, maximizers and best price concerns dominated the copay assistance landscape in 2021. Here is an update on the most prominent developments in this area over the last six months.

By Jason Zemcik, Vice President, Patient Affordability, TrialCard • Feb. 22, 2022

Pressed by Wall Street, pharma executives signal openness to M&A

Despite tumbling biotech valuations, however, several said they still prefer smaller-sized "bolt-on" deals to larger, potentially more disruptive, transactions.

By Ned Pagliarulo • Feb. 7, 2022

Intellia, expanding in gene editing, buys startup Rewrite for $45M

Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's. 

By Ned Pagliarulo • Feb. 3, 2022

Biogen, facing pressure on all sides, sells stake in biosimilars business

The biotech will sell the roughly 50% stake it holds in a biosimilars joint venture to Samsung Biologics for as much as $2.3 billion — cash that analysts expect the drugmaker to invest in M&A.

By Ned Pagliarulo , Jacob Bell • Jan. 28, 2022

J&J 'constantly looking' at biotech M&A, but focused on small, mid-sized deals

Despite sliding stock prices, biotechs aren't "on sale," J&J CFO Joe Wolk said Tuesday. "It's really hard to say whether there's been a capitulation, or a recognition, that values have come down."

By Ned Pagliarulo • Jan. 25, 2022

Antitrust regulators aim to revamp merger guidelines, signaling threat to health sector deals

The news sparked headlines about an attempt by regulators to target big tech, but it could have serious implications for healthcare, too. 

By Samantha Liss • Jan. 19, 2022

UCB to buy Zogenix for nearly $2B in 'first step' for M&A in 2022

The acquisition will give the Belgian pharma access to an epilepsy drug that won U.S. approval in June 2020 but that Zogenix has struggled to sell. 

By Ben Fidler • Jan. 19, 2022

5 questions facing biotech M&A in 2022

Analysts expect that deal engines are ready to start firing again following the recent quiet period. Still, uncertainty remains about how biopharma acquisitions could play out in the coming months.

By Jacob Bell • Jan. 12, 2022

JPM22: M&A anxiety, Roche's comeback plan and Vir's omicron moment

Pharma executives fielded many questions about their dealmaking intentions on the conference's second day, while Roche outlined its plan to compete against Merck and Bristol Myers in cancer immunotherapy.

By Ben Fidler , Ned Pagliarulo • Jan. 11, 2022

Pfizer expands into gene editing with Beam research deal

Pfizer's work with mRNA vaccines led it to explore other applications of the technology, resulting in a multiyear partnership with the high-profile biotech Beam Therapeutics on gene editing treatments for rare diseases.

By Ned Pagliarulo • Jan. 10, 2022

Lilly pours more money into genetic treatments for neurological diseases

For $50 million, Lilly has secured rights to a technology that's meant to transport nucleic acid therapies in a way that's more targeted and better tolerated than other methods.

By Jacob Bell • Jan. 6, 2022

Biogen brings in a successor to Spinraza

The company spent $60 million to secure global rights to an experimental drug developed by Ionis Pharmaceuticals to treat spinal muscular atrophy.

By Jacob Bell • Jan. 4, 2022

Novartis ups investment in gene therapy for the eye with $800M buyout

The deal for Gyroscope Therapeutics, worth up to $1.5 billion, gives the Swiss pharma access to a treatment for a type of age-related blindness as well as new means of delivering drugs into the eye.

By Jonathan Gardner • Dec. 22, 2021

Sanofi to buy cancer immunotherapy biotech for $1B

The French drugmaker is interested in Amunix Pharmaceuticals' technology, which could allow for more precise delivery of biologic drugs into cancerous tissue.

By Ned Pagliarulo • Dec. 21, 2021

Bristol Myers returns to Immatics for a dual-targeting cancer drug

The pharma has expanded an alliance with a German biotech by paying $150 million for a drug candidate that executives hope can have "cell therapy-like efficacy" for solid tumors. 

By Ben Fidler • Dec. 14, 2021

Arena, completing its turnaround, sells to Pfizer for nearly $7 billion

Pfizer will pay $100 per share to acquire Arena and the portfolio of inflammatory disease medicines it developed in the wake of a disappointing drug launch.

By Ben Fidler • Updated Dec. 13, 2021

Sobi buyout breaks down

Three months after proposing a roughly $8 billion acquisition of Sobi, the investment firms Advent International and GIC have withdrawn their offer.

By Jacob Bell • Dec. 3, 2021

Novartis pays $150M for access to UCB's Parkinson's drug

UCB's experimental pill is one of the most advanced projects that's aimed at blocking accumulation of an abnormal protein in patients' brains.

By Jonathan Gardner • Dec. 2, 2021

GSK sets sights on brain diseases through Oxford partnership

Equipped with $40 million in funding, a new institute from GSK and Oxford will initially focus on developing treatments for Alzheimer's, Parkinson's, ALS and other neurological conditions.

By Jacob Bell • Dec. 2, 2021